SEARCH

SEARCH BY CITATION

References

  • 1
    Ramirez M. Horse asthma following blood transfusion: Report of a case. Jama 1919;73:984.
  • 2
    Prausnitz C, Küstner H. Studieu über die Oberempfindlichkeit Zbl Bakt 1921;86:160175.
  • 3
    Ishizaka K, Ishizaka T, Hornbrook MM. Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J Immunol 1966;97:7585.
  • 4
    Ishizaka K, Ishizaka T. Identification of gamma-E-antibodies as a carrier of reaginic activity. J Immunol 1967;99:11871198.
  • 5
    Johansson SG. Raised levels of a new immunoglobulin class (IgND) in asthma. Lancet 1967;2:951953.
  • 6
    Bennich HH, Ishizaka K, Johansson SG et al. Immunoglobulin E: a new class of human immunoglobulin. Immunology 1968;15:323324.
  • 7
    Johansson SG, Hourihane JO, Bousquet J et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001;56:813824.
  • 8
    Anonymous. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J 1998;12:315335.
  • 9
    Banner AS. The increase in asthma prevalence. Chest 1995;108:301302.
  • 10
    Beasley R, Crane J, Lai CK, Pearce N. Prevalence and etiology of asthma. J Allergy Clin Immunol 2000;105:S466S472.
  • 11
    Doyle R. Asthma worldwide. Sci Am 2000;282:30.
  • 12
    Burney P. Epidemiology of asthma. Allergy 1993;48:1721.
  • 13
    Mitchell EA. Asthma epidemiology: clues and puzzles. Pediatr Pulmonol Suppl 1999;18:3133.
  • 14
    Woolcock AJ. Learning from asthma deaths. BMJ 1997;314:14271428.
  • 15
    Holgate ST. The epidemic of allergy and asthma. Nature 1999;402:B2B4.
  • 16
    Coffman RL, Seymour BW, Lebman DA et al. The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunol Rev 1988;102:528.
  • 17
    Coffman RL, Carty J. A T cell activity that enhances polyclonal IgE production and its inhibition by interferon-gamma. J Immunol 1986;136:949954.
  • 18
    Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:23482357.
  • 19
    Lebman DA, Coffman RL. Interleukin 4 causes isotype switching to IgE in T cell-stimulated clonal B cell cultures. J Exp Med 1988;168:853862.
  • 20
    Jabara HH, Schneider LC, Shapira SK et al. Induction of germline and mature Ce transcripts in human B cells stimulated with rIL-4 and EBV. J Immunol 1990;145:34683473.
  • 21
    Vercelli D, Jabara HH, Arai K, Geha RS. Induction of human IgE synthesis requires interleukin 4 and T–B cell interaction involving the T cell receptor/CD3 complex and MHC-class II antigens. J Exp Med 1989;169:12951307.
  • 22
    Jabara HH, Fu SM, Geha RS, Vercelli D. Synergism between anti-CD40 mAb and IL-4 in the induction of IgE synthesis by highly purified human B cells. J Exp Med 1990;172:18611864.
  • 23
    Blank U, Ra C, Miller L, White K, Metzger H, Kinet JP. Complete structure and expression in transfected cells of high affinity IgE receptor. Nature 1989;337:187189.
  • 24
    Gounni AS, Lamkhioued B, Delaporte E et al. The high-affinity IgE receptor on eosinophils: from allergy to parasites or from parasites to allergy? J Allergy Clin Immunol 1994;94:12141216.
  • 25
    Kehry MR, Yamashita LC. Low-affinity IgE receptor (CD23) function on mouse B cells: role in IgE-dependent antigen focusing. Proc Nat Acad Sci USA 1989;86:75567560.
  • 26
    Conrad DH. Fc epsilon RII/CD23: the low affinity receptor for IgE. Ann Rev Immunol 1990;8:623645.
  • 27
    Holgate ST, Robinson C, Church MK, Howarth PH. The release and role of inflammatory mediators in asthma. Clin Immunol Rev 1985;4:241288.
  • 28
    Holgate ST. Contribution of inflammatory mediators to the immediate asthmatic reaction. Am Rev Respir Dis 1987;135:S57S62.
  • 29
    Bradding P, Roberts JA, Britten KM et al. Interleukin-4-5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994;10:471480.
  • 30
    Galli SJ, Wershil BK, Gordon JR, Martin TR. Mast cells: immunologically specific effectors and potential sources of multiple cytokines during IgE-dependent responses. Ciba Found Symp 1989;147:5365; discussion 65–73.
  • 31
    Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, Holdaway MD. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991;325:10671071.
  • 32
    Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989;320:271277.
  • 33
    Burrows B, Martinez FD, Cline MG, Lebowitz MD. The relationship between parental and children's serum IgE and asthma. Am J Respir Crit Care Med 1995;152:14971500.
  • 34
    Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates [see comments]. N Engl J Med 1995;332:133138.
  • 35
    Oehling AG Jr, Walker C, Virchow JC, Blaser K. Correlation between blood eosinophils, T-helper cell activity markers and pulmonary function in patients with allergic and intrinsic asthma. J Invest Allergol Clin Immunol 1992;2:295299.
  • 36
    Humbert M, Grant JA, Taborda-Barata L et al. High-affinity IgE receptor (FcepsilonRI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma. Am J Respir Crit Care Med 1996;153:19311937.
  • 37
    Humbert M, Menz G, Ying S et al. The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol Today 1999;20:528533.
  • 38
    Roehr CC, Reibel S, Ziegert M, Sommerfeld C, Wahn U, Niggemann B. Atopy patch tests, together with determination of specific IgE levels, reduce the need for oral food challenges in children with atopic dermatitis. J Allergy Clin Immunol 2001;107:548553.
  • 39
    Bock SA, Sampson HA. Food allergy in infancy. Pediatr Clin North Am 1994;41:10471067.
  • 40
    International consensus report on diagnosis and management of asthma. Bethesda, MD, USA: National Heart, Lung and Blood Institute, Publication no. 92–3091, 1992.
  • 41
    Norman PS. Modern concepts of immunotherapy. Curr Opin Immunol 1993;5:968973.
  • 42
    Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy Asthma and Immunology. Practice parameters for allergen immunotherapy. J Allergy Clin Immunol 1996;98:10011011.
  • 43
    Fick RBJ, Fox JA, Jardieu PM. Immunotherapy approach to allergic disease. Immunopharmacol 2000;48:307310.
  • 44
    Bryan SA, Leckie MJ, Hansel TT, Barnes PJ. Novel therapy for asthma. Expert Opin Invest Drugs 2000;9:2542.
  • 45
    Barnes PJ. Anti-IgE therapy in asthma: rationale and therapeutic potential. Int Arch Allergy Immunol 2000;123:196204.
  • 46
    Fahy JV. Reducing IgE levels as a strategy for the treatment of asthma. Clin Exp Allergy 2000;30 (Suppl 1):1621.
  • 47
    Heusser C, Jardieu P. Therapeutic potential of anti-IgE antibodies. Curr Opin Immunol 1997;9:805813.
  • 48
    Presta LG, Shields R, O'Connell L et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994;269:2636826373.
  • 49
    Saban R, Haak-Frendscho M, Zine M et al. Human FcERI-IgG and humanized anti-IgE monoclonal antibody MaE11 block passive sensitization of human and rhesus monkey lung. J Allergy Clin Immunol 1994;94:836843.
  • 50
    Presta LG, Lahr SJ, Shields RL et al. Humanization of an antibody directed against IgE. J Immunol 1993;151:26232632.
  • 51
    Fox JA, Hotaling TE, Struble C, Ruppel J, Bates DJ, Schoenhoff MB. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 1996;279:10001008.
  • 52
    MacGlashan D Jr, Bochner BS, Adelman DC et al. Down-regulation of FceRI-expression on human basophils during in vivo treatment with anti-IgE antibody. J Immunol 1997;158:14381445.
  • 53
    Fick RBJ. Anti-IgE as novel therapy for the treatment of asthma. Curr Opin Pulm Med 1999;5:7680.
  • 54
    Jardieu PM, Fick RBJ. IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol 1999;118:112115.
  • 55
    Casale TB, Bernstein IL, Busse WW et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997;100:110121.
  • 56
    Fahy JV, Cockcroft DW, Boulet LP et al. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med 1999;160:10231027.
  • 57
    Boulet LP, Chapman KR, Cote J et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997;155:18351840.
  • 58
    Fahy JV, Fleming HE, Wong HH et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:18281834.
  • 59
    Milgrom H, Fick RBJ, Su JQ et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 1999;341:19661973.
  • 60
    Busse W, Corren J, Lanier BQ et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184190.
  • 61
    Soler M, Matz J, Townley R et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254261.
  • 62
    Milgrom H, Berger W, Nayak A et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108:E36.
  • 63
    Lieberman P, Patterson R. Immunotherapy for atopic disease. Adv Intern Med 1974;19:391411.
  • 64
    Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994;93:413423.
  • 65
    Juniper EF, Guyatt GH, Griffith LE, Ferrie PJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 1996;98:843845.
  • 66
    Malone DC, Lawson KA, Smith DH, Arrighi HM, Battista C. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997;99:2227.
  • 67
    White P, Smith H, Baker N, Davis W, Frew A. Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy? Clin Exp Allergy 1998;28:266270.
  • 68
    Adelroth E, Rak S, Haahtela T et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106:253259.
  • 69
    Anonymous. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Geneva: January 27–29, 1997. Allergy 1998;53:142.
  • 70
    Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468475.
  • 71
    Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy 1995;50:405413.
  • 72
    Kuehr J, Brauburger J, Schauer U et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002;109:274280.
  • 73
    Leckie MJ, Ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:21442148.
  • 74
    Bryan SA, O'Connor BJ, Matti S et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:21492153.
  • 75
    Blumchen K, Kallinich T, Hamelmann E. Interleukin-5: a novel target for asthma therapy. Expert Opin Biol Ther 2001;1:433453.
  • 76
    Barnes PJ. Cytokine-directed therapies for asthma. J Allergy Clin Immunol 2001;108:S72S76.
  • 77
    Hamelmann E, Gelfand EW. IL-5-induced airway eosinophilia – the key to asthma? Immunol Rev 2001;179:182191.
  • 78
    Hamelmann E, Takeda K, Schwarze J, Vella AT, Irvin CG, Gelfand EW. Development of eosinophilic airway inflammation and airway hyperresponsiveness requires interleukin-5 but not immunoglobulin E or B lymphocytes [see comments]. Am J Respir Cell Mol Biol 1999;21:480489.
  • 79
    Oettgen HC, Martin TR, Wynshaw BA, Deng C, Drazen JM, Leder P. Active anaphylaxis in IgE-deficient mice. Nature 1994;370:367370.
  • 80
    Takeda K, Hamelmann E, Joetham A et al. Development of eosinophilic airway inflammation and airway hyperresponsiveness in mast cell-deficient mice. J Exp Med 1997;186:449454.
  • 81
    Hamelmann E, Cieslewicz G, Schwarze J et al. Anti-interleukin 5 but not anti-IgE prevents airway inflammation and airway hyperresponsiveness. Am J Respir Crit Care Med 1999;160:934941.